Alcobra Ltd. (ADHD) Stock Price Down 15.7%
Shares of Alcobra Ltd. (NASDAQ:ADHD) traded down 15.7% on Tuesday . The stock traded as low as $3.86 and last traded at $4.46, with a volume of 563,980 shares changing hands. The stock had previously closed at $5.29.
Several analysts have recently weighed in on the company. Zacks Investment Research upgraded Alcobra from a “sell” rating to a “hold” rating in a research note on Tuesday, July 26th. Canaccord Genuity assumed coverage on Alcobra in a research note on Tuesday, June 7th. They set a “buy” rating for the company. Roth Capital restated a “buy” rating and set a $12.00 target price on shares of Alcobra in a research note on Tuesday, June 21st. Cantor Fitzgerald restated a “buy” rating and set a $16.00 target price on shares of Alcobra in a research note on Wednesday. Finally, Barclays PLC assumed coverage on Alcobra in a research note on Monday, August 1st. They set an “equal weight” rating and a $8.00 target price for the company. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Alcobra presently has a consensus rating of “Buy” and an average price target of $10.96.
The company’s market capitalization is $135.88 million. The company’s 50-day moving average price is $4.68 and its 200 day moving average price is $4.55.
Alcobra (NASDAQ:ADHD) last released its quarterly earnings data on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01. Analysts predict that Alcobra Ltd. will post ($0.97) EPS for the current year.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.